Salarius Pharmaceuticals Inc (SLRX): Price and Financial Metrics
SLRX Price/Volume Stats
| Current price | $0.74 | 52-week high | $6.25 |
| Prev. close | $0.68 | 52-week low | $0.61 |
| Day low | $0.74 | Volume | 2,816 |
| Day high | $0.74 | Avg. volume | 115,301 |
| 50-day MA | $0.81 | Dividend yield | N/A |
| 200-day MA | $1.55 | Market Cap | 2.69M |
SLRX Stock Price Chart Interactive Chart >
Salarius Pharmaceuticals Inc (SLRX) Company Bio
Salarius Pharmaceuticals Inc is a clinical-stage oncology company. The Company specializes in targeting the epigenetic causes of cancers and developing treatments for patients. Salarius Pharmaceuticals serves patients and customers in the State of Texas.
Latest SLRX News From Around the Web
Below are the latest news stories about SALARIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SLRX as an investment opportunity.
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business UpdateFDA removed partial clinical hold for Ewing sarcoma Phase 1/2 study with seclidemstat SP-3164 targeted protein degrader received Investigational New Drug clearance from FDA Company to explore strategic alternatives and implement measures to extend its resources HOUSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new |
SLRX Pursuing Strategic AlternativesBy Brad Sorensen, CFA NASDAQ:SLRX READ THE FULL SLRX RESEARCH REPORT Salarius Pharmaceuticals (NASDAQ:SLRX) recently announced that it was exploring “strategic alternatives” and cutting costs in order to extend its resources. We are disappointed in this announcement as we continue to believe in the science behind the treatments being developed by Salarius. However, we understand that funding has |
Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its ResourcesHOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced plans to explore strategic alternatives and implement measures to extend its resources. “The second quarter and recent weeks were highlighted by significant advancements in both of our development programs, but after a review o |
SLRX Continues Cancer Fight with Phase I Trial ApprovalBy Brad Sorensen, CFA NASDAQ:SLRX READ THE FULL SLRX RESEARCH REPORT • Salarius (NASDAQ:SLRX) announced that it has received FDA clearance of SP-3164 Investigational New Drug Application (NDA) to begin a Phase I clinical trial in relapsed/refractory Non-Hodgkin Lymphoma patients. o SP-3164 is explained in more detail below, but this novel targeted protein degrader is one of the compounds being |
Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma PatientsThe trial will assess the safety and preliminary efficacy of Salarius’ novel targeted protein degrader SP-3164; Patient dosing expected to begin in 2H 2023 The trial will also assess the utility of a gene signature to identify patients that are potentially sensitized to SP-3164 treatment and may be more likely to respond HOUSTON, July 11, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degrada |
SLRX Price Returns
| 1-mo | N/A |
| 3-mo | -50.99% |
| 6-mo | N/A |
| 1-year | -84.44% |
| 3-year | -96.36% |
| 5-year | -99.76% |
| YTD | -51.63% |
| 2022 | -87.65% |
| 2021 | -45.54% |
| 2020 | -75.93% |
| 2019 | -54.18% |
| 2018 | -90.54% |
Loading social stream, please wait...